Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), has entered into an exclusive licensing agreement with the Affiliated Hospital of Southwest Medical University. The agreement pertains to TBM-001, a radionuclide drug conjugate (RDC) designed for early diagnosis and precision therapy of tumor bone metastasis.
Global Rights and Financial Terms of the Agreement
According to the terms of the agreement, Kelun-Biotech will secure exclusive rights to research, develop, and commercialize TBM-001 on a global scale. The company will pay the hospital an upfront fee and milestone payments totaling RMB 38.5 million (USD 5.3 million), in addition to net sales commission and other considerations.
Co-Development of Additional RDC Drugs
The partnership extends beyond TBM-001, as both parties have initiated the co-development of other radionuclide drug conjugates. This collaborative effort aims to expand the portfolio of precision medicine options for cancer treatment and diagnostics.-Fineline Info & Tech
